Two new papers, published simultaneously in Nature Communications and led by researchers at 黑料不打烊 University, offer promise that a drug currently used to treat estrogen positive breast cancer may be effective in treating two different types of cancer, one rare and one common form.

Screening for genes whose risk association with breast cancer has yet to be proven is not justified and potentially harmful, argue an international team of leading geneticists and oncologists in a paper published this week in the prestigious New England Journal of Medicine.